Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (50.0%)
N/A2 (50.0%)

Trials by Status

not_yet_recruiting125%
completed250%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
withdrawnphase_1

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

NCT05909527
not_yet_recruitingnot_applicable

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

NCT07008872
completednot_applicable

Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

NCT04938115
completedphase_1

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

NCT04572308

Clinical Trials (4)

Showing 4 of 4 trials
NCT05909527Phase 1

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

Withdrawn
NCT07008872Not Applicable

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

Not Yet Recruiting
NCT04938115Not Applicable

Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Completed
NCT04572308Phase 1

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4